Pegylated liposomal doxorubicin : Metamorphosis of an old drug into a new form of chemotherapyGABIZON, Alberto A.Cancer investigation. 2001, Vol 19, Num 4, pp 424-436, issn 0735-7907Article

Liposomal drug carrier systems in cancer chemotherapy: Current status and future prospectsGABIZON, Alberto A.Journal of drug targeting. 2002, Vol 10, Num 7, pp 535-538, issn 1061-186X, 4 p.Article

Her2-targeted pegylated liposomal doxorubicin: Retention of target-specific binding and cytotoxicity after in vivo passageSHMEEDA, Hilary; TZEMACH, Dina; MAK, Lidia et al.Journal of controlled release. 2009, Vol 136, Num 2, pp 155-160, issn 0168-3659, 6 p.Article

Pharmacological basis of pegylated liposomal doxorubicin: Impact on cancer therapyGABIZON, Alberto; SHMEEDA, Hilary; GRENADER, Tal et al.European journal of pharmaceutical sciences. 2012, Vol 45, Num 4, pp 388-398, issn 0928-0987, 11 p.Conference Paper

Significant drug interaction : Phenytoin toxicity due to erlotinibGRENADER, Tal; GIPPS, Maya; SHAVIT, Linda et al.Lung cancer. 2007, Vol 57, Num 3, pp 404-406, issn 0169-5002, 3 p.Article

Phase I study of doxil-cisplatin combination chemotherapy in Patients with advanced malignanciesLYASS, Olga; HUBERT, Ayala; GABIZON, Alberto A et al.Clinical cancer research. 2001, Vol 7, Num 10, pp 3040-3046, issn 1078-0432Article

Pharmacokinetics of pegylated liposomal doxorubicin: Review of animal and human studiesGABIZON, Alberto; SHMEEDA, Hilary; BARENHOLZ, Yechezkel et al.Clinical pharmacokinetics. 2003, Vol 42, Num 5, pp 419-436, issn 0312-5963, 18 p.Article

Activation of complement by therapeutic liposomes and other lipid excipient-based therapeutic products: Prediction and preventionSZEBENI, Janos; MUGGIA, Franco; GABIZON, Alberto et al.Advanced drug delivery reviews. 2011, Vol 63, Num 12, pp 1020-1030, issn 0169-409X, 11 p.Article

An open-label study to evaluate dose and cycle dependence of the pharmacokinetics of pegylated liposomal doxorubicinGABIZON, Alberto; ISACSON, Rut; ROSENGARTEN, Ora et al.Cancer chemotherapy and pharmacology. 2008, Vol 61, Num 4, pp 695-702, issn 0344-5704, 8 p.Article

Dose dependency of pharmacokinetics and therapeutic efficacy of pegylated liposomal doxorubicin (DOXIL) in murine modelsGABIZON, Alberto; TZEMACH, Dinah; MAK, Lidia et al.Journal of drug targeting. 2002, Vol 10, Num 7, pp 539-548, issn 1061-186X, 10 p.Article

Tumor cell targeting of liposome-entrapped drugs with phospholipid-anchored folic acid-PEG conjugatesGABIZON, Alberto; SHMEEDA, Hilary; HOROWITZ, Aviva T et al.Advanced drug delivery reviews. 2004, Vol 56, Num 8, pp 1177-1192, issn 0169-409X, 16 p.Article

Improved therapeutic activity of folate-targeted liposomal doxorubicin in folate receptor-expressing tumor modelsGABIZON, Alberto; TZEMACH, Dina; GORIN, Jenny et al.Cancer chemotherapy and pharmacology. 2010, Vol 66, Num 1, pp 43-52, issn 0344-5704, 10 p.Article

In vivo fate of folate-targeted polyethylene-glycol liposomes in tumor-bearing miceGABIZON, Alberto; HOROWITZ, Aviva T; GOREN, Dorit et al.Clinical cancer research. 2003, Vol 9, Num 17, pp 6551-6559, issn 1078-0432, 9 p.Article

Skin toxic effects of polyethylene glycol-coated liposomal doxorubicinLOTEM, Michal; HUBERT, Ayala; LYASS, Olga et al.Archives of dermatology (1960). 2000, Vol 136, Num 12, pp 1475-1480, issn 0003-987XArticle

Liposome imaging agents in personalized medicinePETERSEN, Anncatrine L; HANSEN, Anders E; GABIZON, Alberto et al.Advanced drug delivery reviews. 2012, Vol 64, Num 13, pp 1417-1435, issn 0169-409X, 19 p.Article

Ultrasound triggered release of cisplatin from liposomes in murine tumorsSCHROEDER, Avi; HONEN, Reuma; TURJEMAN, Keren et al.Journal of controlled release. 2009, Vol 137, Num 1, pp 63-68, issn 0168-3659, 6 p.Article

Reduced toxicity and superior therapeutic activity of a mitomycin C lipid-based prodrug incorporated in pegylated liposomesGABIZON, Alberto A; TZEMACH, Dinah; HOROWITZ, Aviva T et al.Clinical cancer research. 2006, Vol 12, Num 6, pp 1913-1920, issn 1078-0432, 8 p.Article

Challenges and Key Considerations of the Enhanced Permeability and Retention Effect for Nanomedicine Drug Delivery in OncologyPRABHAKAR, Uma; MAEDA, Hiroshi; JAIN, Rakesh K et al.Cancer research (Chicago, Ill.). 2013, Vol 73, Num 8, pp 2412-2417, issn 0008-5472, 6 p.Article

Therapeutic efficacy of a lipid-based prodrug of mitomycin C in pegylated liposomes: Studies with human gastro-entero-pancreatic ectopic tumor modelsGABIZON, Alberto; AMITAY, Yasmine; TZEMACH, Dina et al.Journal of controlled release. 2012, Vol 160, Num 2, pp 245-253, issn 0168-3659, 9 p.Article

Words Matter: Distinguishing Personalized Medicine and Biologically Personalized TherapeuticsCHERNY, Nathan I; DE VRIES, Elisabeth G. E; EMANUEL, Linda et al.Journal of the National Cancer Institute. 2014, Vol 106, Num 12, issn 0027-8874, 321.1-321.5Article

Factors affecting the pharmacokinetics of pegylated liposomal doxorubicin in patientsLA-BECK, Ninh M; ZAMBONI, Beth A; GABIZON, Alberto et al.Cancer chemotherapy and pharmacology. 2012, Vol 69, Num 1, pp 43-50, issn 0344-5704, 8 p.Article

Controlling liposomal drug release with low frequency ultrasound : Mechanism and feasibilitySCHROEDER, Avi; AVNIR, Yuval; WEISMAN, Sarah et al.Langmuir. 2007, Vol 23, Num 7, pp 4019-4025, issn 0743-7463, 7 p.Article

Cardiac safety of liposomal anthracyclinesEWER, Michael S; MARTIN, Francis J; HENDERSON, I. Craig et al.Seminars in oncology. 2004, Vol 31, Num 6, pp 161-181, issn 0093-7754, 21 p., SUP13Article

Efficacy and safety of liposomal anthracyclines in phase I/II clinical trialsALBERTS, David S; MUGGIA, Franco M; STEWART, Simon J et al.Seminars in oncology. 2004, Vol 31, Num 6, pp 53-90, issn 0093-7754, 38 p., SUP13Article

The role of the liposomal anthracyclines and other systemic therapies in the management of advanced breast cancerROBERT, Nicholas J; VOGEL, Charles L; WINER, Eric P et al.Seminars in oncology. 2004, Vol 31, Num 6, pp 106-146, issn 0093-7754, 41 p., SUP13Article